RecruitingPhase 2NCT05526079

Watchful Waiting for Complete Responders to Therapy in Rectal Cancer

Treatment of T2-T3/NO-N+ Adenocarcinoma of the Rectum by Neoadjuvant Chemotherapy (FOLFOX) Followed by Preoperative Chemo (Fluorouracil / Capecitabine)-Radio Therapy (CRT) With Watchful Waiting for Complete Responders


Sponsor

Henry Ford Health System

Enrollment

30 participants

Start Date

Jul 10, 2018

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of this project is to determine if in a selected group of patients, at higher risk of wound dehiscence and other complications, treatment by local excision and management by a "watchful waiting" or an initial "non-operative management" approach, with an offer of radical resection only to those patients whose tumors demonstrate "regrowth" will maintain acceptable local control and overall survival rate for the whole cohort.


Eligibility

Min Age: 18 YearsMax Age: 95 Years

Inclusion Criteria5

  • Age ≥ 18 years
  • Diagnosis of rectal invasive adenocarcinoma
  • Tumor in the low rectum lying \< 4 cm from the anal verge
  • Clinical stage T3/N0-N1M0.
  • Patients with low T2 who will need abdominal perineal resection are also eligible.

Exclusion Criteria4

  • Age less than 18 years
  • Other forms of cancer
  • Tumors \>= 4 cm from the anal verge
  • Tumors of other clinical stages than listed above

Interventions

OTHERWatchfuf waiting

Careful review of patient response with the hope of avoiding radical surgery.


Locations(1)

Ascension St. John Hospital

Detroit, Michigan, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05526079


Related Trials